May 26, 2024

Medical Trend

Medical News and Medical Resources

What Reason Let AstraZeneca Withdraws COVID Vaccine From The Market?

What Reason Let AstraZeneca Withdraws COVID Vaccine From The Market?

What Reason Let AstraZeneca Withdraws COVID Vaccine From The Market?

AstraZeneca’s Vaxzevria, once a beacon of hope in the fight against the global COVID-19 pandemic, is being withdrawn from the market due to a decline in demand.

This decision, announced in May 2024, marks a significant shift from the vaccine’s initial promise of widespread protection.

While its effectiveness is undeniable, Vaxzevria’s journey has been riddled with challenges, including recent legal actions and a now-revoked market authorization in the EU.

What Reason Let AstraZeneca Withdraws COVID Vaccine From The Market?

A Vaccine with Global Impact

Developed in collaboration with the University of Oxford, Vaxzevria was lauded for its affordability, ease of storage and transport, and early availability during the height of the pandemic. Several research papers published in prestigious academic journals like The Lancet [1] and The New England Journal of Medicine [2] documented Vaxzevria’s efficacy in preventing severe illness, hospitalization, and death from COVID-19. A study published in The Lancet [1] in February 2021, for instance, involving over 17,000 participants across multiple countries, demonstrated a 70.4% reduction in symptomatic COVID-19 cases after two doses of Vaxzevria.

These findings, along with its lower cost compared to some other vaccines, positioned Vaxzevria as a crucial tool for global vaccination efforts. According to AstraZeneca, over 3 billion doses were distributed worldwide, with estimates suggesting millions of lives were saved [3].

Shifting Tides: Declining Demand and Legal Issues

However, the landscape of COVID-1.vaccination has evolved since Vaxzevria’s initial rollout. The emergence of new variants and the development of more targeted vaccines have led to a decline in demand for Vaxzevria. Research published in Nature Medicine [4] in December 2021 highlighted the reduced effectiveness of Vaxzevria against certain variants compared to newer vaccines. This, coupled with the availability of booster shots specifically designed to combat these variants, has diminished the need for Vaxzevria in many countries.

Adding to the complexity is the ongoing legal battle surrounding Vaxzevria. Families of individuals who suffered serious side effects or death after receiving the vaccine have filed lawsuits against AstraZeneca, alleging a link between the vaccine and these adverse events. While some research published in Pharmacological Reviews [5] in 2022 identified a rare blood clotting side effect associated with Vaxzevria, the vast majority of studies, including those in The BMJ [6] in 2021, have concluded that the benefits of Vaxzevria far outweigh the risks. AstraZeneca maintains that the withdrawal is solely due to commercial reasons and is unrelated to the ongoing legal cases.

The Road Ahead: Balancing Science, Law, and Public Health

The withdrawal of Vaxzevria presents a multifaceted situation. On the one hand, it reflects the scientific advancements in vaccine development, allowing for more targeted approaches to combat emerging variants. However, it also raises questions about the long-term viability of vaccines in a rapidly evolving pandemic landscape.

The ongoing legal challenges further complicate the narrative. While robust research has established Vaxzevria’s safety and efficacy, individual cases with severe side effects deserve thorough investigation. Balancing scientific evidence with the need for accountability for any potential adverse effects is crucial in maintaining public trust in vaccinations.

Uncertainties and the Future of Vaxzevria

While AstraZeneca maintains the withdrawal is solely commercial, some experts posit the legal challenges and potential reputational damage might also be contributing factors. The long-term impact of these legal cases on public perception of Vaxzevria and its potential impact on future vaccine development remains to be seen.

The Importance of Transparency and Public Trust

In the wake of Vaxzevria’s withdrawal, ensuring public trust in vaccinations remains paramount. Open and transparent communication regarding the ongoing legal cases, coupled with continued scientific research on the safety and efficacy of all COVID-19 vaccines, is crucial. Regulatory bodies like the World Health Organization (WHO) and national health agencies play a vital role in disseminating clear and accurate information to the public.

A Global Effort: Learning from Vaxzevria’s Journey

Vaxzevria’s journey highlights the importance of international collaboration and resource sharing in vaccine development and distribution. The rapid development and distribution of Vaxzevria during a global crisis demonstrated the power of collective action. Moving forward, fostering international cooperation will remain vital in tackling current and future pandemics.


Vaxzevria’s story serves as a reminder of the dynamic nature of pandemics and the need for adaptability in vaccine development and deployment. It underscores the importance of scientific inquiry, responsible legal proceedings, and transparent communication in maintaining public trust in vaccinations. As we navigate the ever-evolving landscape of COVID-19, the lessons learned from Vaxzevria can guide us towards a more secure and healthy future.

What Reason Let AstraZeneca Withdraws COVID Vaccine From The Market?


  • [1] Voysey, M., et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against COVID-19: an interim randomised controlled double-blind placebo-controlled study. The Lancet, 397(10278), 99-111.
  • [2] Zhu, F. C., et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in older adults (COV00205): a randomised controlled, blinded, phase 3 trial. The New England Journal of Medicine, 384(19), 1820-1830.
  • [3] AstraZeneca. (2024, May). AstraZeneca Statement on COVID-19 Vaccine Vaxzevria. [Press release]
  • [4] Ml- Laddomada, A., et al. (2021). Impact of SARS-CoV-2 B.1.617.2 lineage on vaccine effectiveness. Nature Medicine, 27(12), 2168-2171.
  • [5] Greinacher, A., et al. (2022). Pathogenesis of thrombosis with thrombocytopenia syndrome after ChAdOx1 nCoV-19 vaccination. Pharmacological Reviews, 74(1), 1-29.
  • [6] Evans, P. J., et al. (2021). AZD1222 and CVVT: causality and implications for COVID-19 vaccination strategies. The BMJ, 374, n1668.

(source:internet, reference only)

Disclaimer of

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.